Overview

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Status:
Not yet recruiting

Trial end date:
2028-01-30

Target enrollment:

Participant gender:

Summary

This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Heinrich-Heine University, Duesseldorf

Collaborator:

Koordinierungszentrum für Klinische Studien - Duesseldorf

Treatments:

Amsacrine
Mycophenolic Acid
Tacrolimus
Venetoclax